Press Releases August 6, 2026 05:15 PM

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

LeMaitre Vascular to Present at the 11th Annual Needham Virtual MedTech & Diagnostics Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
LMAT

LeMaitre Vascular, a medical device company specializing in peripheral vascular disease treatment, will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, engaging with investors to discuss its products and market strategies.

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LMAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LeMaitre Vascular manufactures devices primarily for vascular surgeons treating peripheral vascular disease.
  • The company is participating in a major virtual investor conference targeting the MedTech and diagnostics sector.
  • Peripheral vascular disease affects over 200 million people worldwide, indicating a large potential market for LeMaitre's products.

BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
[email protected]


Risks

  • The success of LeMaitre's market engagement depends on investor reception at the conference, which is uncertain.
  • Peripheral vascular disease treatment is a competitive market with evolving technologies and regulatory challenges.
  • Market acceptance and reimbursement policies for their vascular devices could impact future revenues.

More from Press Releases

Destination XL Group, Inc. Appoints Current Chairman Lionel Conacher as Interim Chief Executive Officer Aug 6, 2026 Strawberry Fields REIT Announces Second Quarter 2026 Operating Results Aug 6, 2026 Strawberry Fields REIT Announces Q3 2026 Cash Dividend of $0.17 per Common Share Aug 6, 2026 Oxbridge Re Announces 2026 Second Quarter Results on August 13, 2026 Aug 6, 2026 Ready Capital Corporation Reports Second Quarter 2026 Results Aug 6, 2026